Globus Medical (GMED) Offers Light Guidance but Needham Sees Through Chatter and Raises PT to $75
Tweet Send to a Friend
Needham & Company analyst Mike Matson raised the price target on Globus Medical (NYSE: GMED) to $75.00 (from $65.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
